SDZNY Quote, Financials, Valuation and Earnings

Addex Therapeutics has a net margin of -39.83% compared to Sandoz Group AG's net margin of -2841.85%. Sandoz Group AG's return on equity of -- beat Addex Therapeutics's return on equity of 91.08%.

Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 297.87%. Given that Addex Therapeutics has higher upside potential than Sandoz Group AG, analysts believe Addex Therapeutics is more attractive than Sandoz Group AG.

Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 1.646, suggesting its more volatile than the S&P 500 by 64.6%.

Sandoz Group AG has a quarterly dividend of $0.73 per share corresponding to a yield of 1.28%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.

Sandoz Group AG quarterly revenues are $74.4M, which are larger than Addex Therapeutics quarterly revenues of $62.3K. Sandoz Group AG's net income of -$29.6M is lower than Addex Therapeutics's net income of -$1.6M. Notably, Sandoz Group AG's price-to-earnings ratio is 26.84x while Addex Therapeutics's PE ratio is 1.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 2.38x versus 20.63x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CRISPR Therapeutics AG has a net margin of -39.83% compared to Sandoz Group AG's net margin of -106.6%. Sandoz Group AG's return on equity of -- beat CRISPR Therapeutics AG's return on equity of -18.65%.

Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.80 which suggests that it could grow by 25.59%. Given that CRISPR Therapeutics AG has higher upside potential than Sandoz Group AG, analysts believe CRISPR Therapeutics AG is more attractive than Sandoz Group AG.

Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.822, suggesting its more volatile than the S&P 500 by 82.156%.

Sandoz Group AG has a quarterly dividend of $0.73 per share corresponding to a yield of 1.28%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

Sandoz Group AG quarterly revenues are $74.4M, which are larger than CRISPR Therapeutics AG quarterly revenues of $35M. Sandoz Group AG's net income of -$29.6M is higher than CRISPR Therapeutics AG's net income of -$136M. Notably, Sandoz Group AG's price-to-earnings ratio is 26.84x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 2.38x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

NLS Pharmaceutics has a net margin of -39.83% compared to Sandoz Group AG's net margin of --. Sandoz Group AG's return on equity of -- beat NLS Pharmaceutics's return on equity of --.

Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 10710.81%. Given that NLS Pharmaceutics has higher upside potential than Sandoz Group AG, analysts believe NLS Pharmaceutics is more attractive than Sandoz Group AG.

Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sandoz Group AG has a quarterly dividend of $0.73 per share corresponding to a yield of 1.28%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.

Sandoz Group AG quarterly revenues are $74.4M, which are larger than NLS Pharmaceutics quarterly revenues of --. Sandoz Group AG's net income of -$29.6M is higher than NLS Pharmaceutics's net income of --. Notably, Sandoz Group AG's price-to-earnings ratio is 26.84x while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 2.38x versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.

BeOne Medicines has a net margin of -39.83% compared to Sandoz Group AG's net margin of 0.11%. Sandoz Group AG's return on equity of -- beat BeOne Medicines's return on equity of -11.54%.

Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines has an analysts' consensus of $335.45 which suggests that it could grow by 13.89%. Given that BeOne Medicines has higher upside potential than Sandoz Group AG, analysts believe BeOne Medicines is more attractive than Sandoz Group AG.

Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BeOne Medicines has a beta of 0.282, suggesting its less volatile than the S&P 500 by 71.823%.

Sandoz Group AG has a quarterly dividend of $0.73 per share corresponding to a yield of 1.28%. BeOne Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -- of its earnings as a dividend. BeOne Medicines pays out -- of its earnings as a dividend.

Sandoz Group AG quarterly revenues are $74.4M, which are smaller than BeOne Medicines quarterly revenues of $1.1B. Sandoz Group AG's net income of -$29.6M is lower than BeOne Medicines's net income of $1.3M. Notably, Sandoz Group AG's price-to-earnings ratio is 26.84x while BeOne Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 2.38x versus 7.56x for BeOne Medicines. Usually stocks with elevated PS ratios are considered overvalued.